Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 1
1989 1
1992 1
2003 1
2005 1
2007 3
2008 4
2009 9
2010 5
2011 8
2012 7
2013 11
2014 9
2015 11
2016 3
2017 5
2018 5
2019 5
2020 4
2021 7
2022 9
2023 9
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.
Gelibter A, Asquino A, Strigari L, Zizzari IG, Tuosto L, Scirocchi F, Pace A, Siringo M, Tramontano E, Bianchini S, Bellati F, Botticelli A, Paoli D, Santini D, Nuti M, Rughetti A, Napoletano C. Gelibter A, et al. Among authors: napoletano c. J Transl Med. 2024 Apr 3;22(1):329. doi: 10.1186/s12967-024-05142-6. J Transl Med. 2024. PMID: 38570798 Free PMC article.
MGL Receptor and Immunity: When the Ligand Can Make the Difference.
Zizzari IG, Napoletano C, Battisti F, Rahimi H, Caponnetto S, Pierelli L, Nuti M, Rughetti A. Zizzari IG, et al. Among authors: napoletano c. J Immunol Res. 2015;2015:450695. doi: 10.1155/2015/450695. Epub 2015 Dec 29. J Immunol Res. 2015. PMID: 26839900 Free PMC article. Review.
Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.
Zizzari IG, Di Filippo A, Botticelli A, Strigari L, Pernazza A, Rullo E, Pignataro MG, Ugolini A, Scirocchi F, Di Pietro FR, Rossi E, Gelibter A, Schinzari G, D'Amati G, Rughetti A, Marchetti P, Nuti M, Napoletano C. Zizzari IG, et al. Among authors: napoletano c. Clin Cancer Res. 2022 Mar 1;28(5):1027-1037. doi: 10.1158/1078-0432.CCR-21-2918. Clin Cancer Res. 2022. PMID: 34980602 Free PMC article.
Monoclonal antibodies in gynecological cancer: a critical point of view.
Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, Caccetta J, Rughetti A, Benedetti-Panici P, Nuti M. Bellati F, et al. Among authors: napoletano c. Clin Dev Immunol. 2011;2011:890758. doi: 10.1155/2011/890758. Epub 2011 Dec 26. Clin Dev Immunol. 2011. PMID: 22235224 Free PMC article. Review.
Immune effects of trastuzumab.
Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, Zizzari IG, Ruscito I, Rahimi H, Benedetti-Panici P, Rughetti A. Nuti M, et al. Among authors: napoletano c. J Cancer. 2011;2:317-23. doi: 10.7150/jca.2.317. Epub 2011 May 25. J Cancer. 2011. PMID: 21716848 Free PMC article.
112 results